QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
about
Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and managementVentricular repolarization measures for arrhythmic risk stratificationAntipsychotic Polypharmacy and Corrected QT Interval: A Systematic ReviewCo-Prescription of QT-Interval Prolonging Drugs: An Analysis in a Large Cohort of Geriatric Patients2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures.HIV-1-Tat excites cardiac parasympathetic neurons of nucleus ambiguus and triggers prolonged bradycardia in conscious rats.Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors.Citalopram Overdose: a Fatal Case.Inter-study variability of preclinical in vivo safety studies and translational exposure-QTc relationships--a PKPD meta-analysis.A consensus guideline for antipsychotic drug use for dementia in care homes. Bridging the gap between scientific evidence and clinical practiceDrug-Induced Long-QT and Torsades de Pointes in Elderly Polymedicated PatientsProarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients.QTc Prolongation after Ventricular Septal Defect Repair in Infants.Hypomagnesemia, chronic kidney disease and cardiovascular mortality: pronounced association but unproven causation.A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.Pharmacogenomics study of thiazide diuretics and QT interval in multi-ethnic populations: the cohorts for heart and aging research in genomic epidemiology.Use of quantitative pharmacology tools to improve malaria treatments.Hidradenitis Suppurativa and electrocardiographic changes - a cross-sectional population study.Survey of the use of domperidone and the association with QTc prolongation in general practice.Clinical pharmacists' opportunities to reduce inappropriate prescription of QT-prolonging medications: calls to action.Assessment of myocardial repolarisation parameters in patients with familial Mediterranean fever.Prolongation of the QTc interval in HIV-infected individuals compared to the general population.The effectiveness and limitations of regulatory warnings for the safe prescribing of citalopram.Electrocardiographic P-Wave Duration, QT Interval, T Peak to End Interval and Tp-e/QT Ratio in Pregnancy with Respect to Trimesters.Extreme doses of intravenous methadone for severe pain in two children with cancer.Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature.Predictors of mortality in high-risk patients with QT prolongation in a community hospital.Effect-site concentration of remifentanil for attenuating QTc interval prolongation following intubation in hypertensive female patients.The effects of diltiazem and metoprolol in QTc prolongation due to amitriptyline intoxication.Approach to initiating QT-prolonging oncology drugs in the ambulatory setting.Pain medication and long QT syndrome.
P2860
Q26747032-12749D16-A358-405A-8E16-2BD4D2442582Q26769982-D0AE8DEE-1D65-40F0-B272-567CABBD5FDAQ26801835-9BBECB90-5D7F-4252-A90E-184A173B824FQ28552117-69FC5952-A0C5-463F-82B3-7CA631C465F3Q30653045-94CAC49F-B6A2-470E-9812-216A5AD69908Q33701989-0C76F106-9FC1-4148-BC5E-DBD342E49A2AQ35198387-3BF684D7-7F21-496C-95DE-1416799C0482Q35749126-96F5EFBF-89E0-4E42-BB46-FEF3C64DD686Q36016439-D2266EE1-ED58-4413-A1DD-1855F1AF712CQ36091476-417D0659-59D3-47BB-B8B5-AE371A8F8B0AQ36611478-0C8C056F-5377-4460-B565-FE77F39A6975Q36970774-8637F6FD-646F-4ECD-A93C-6D0EED27373DQ37420089-330BA482-62D8-4020-BEC2-622542206748Q38196961-65051DF1-BCD1-4AAF-A69C-CDCCE52B71EAQ38546437-5EB5C430-D654-4C8A-BEB3-D5CD7EE41E66Q38655838-147137A0-49F2-4D6E-A7C1-6AED30330EE9Q38664529-5FB66F00-6F56-4F4A-89F7-E36664639522Q38698982-0EACC94A-DCEE-4424-92CE-DA725581AF81Q38708586-AFEA1D89-B93B-444D-8367-9CDB421EB55DQ38965997-2D6D322E-9ECF-4535-9AAA-B805F9D121E6Q40043448-8E4DCDDA-9867-4608-8601-CCFE9A8A48CCQ40095042-ADF6CDDE-6F94-4E2C-830D-AF6B601CE031Q40597331-594C0F8B-B7E1-424C-A8E0-4B608EAA1DD1Q40825885-B48FF886-6A70-4199-AB89-3B690190FE3BQ41495525-A5B2B971-443A-4311-AE48-2D01B3FF2FFCQ47118928-6C255C64-A0D5-4442-90A2-9B823B35F891Q47608205-5D5959E9-364B-4440-86CC-CE796EBB64E7Q47685042-9BD24F4C-1AE3-4B69-8D8C-AC254775C7A6Q47742216-1D7B97A9-033E-4D0B-AD1C-BF38690B324CQ49338688-EC52229A-3FD8-4F43-B5EB-CEB5CEBD3487Q49422188-BDEF1E7F-F135-400E-869D-9DDFB307742D
P2860
QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
@ast
QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
@en
type
label
QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
@ast
QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
@en
prefLabel
QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
@ast
QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
@en
P2093
P1476
QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
@en
P2093
Hoang Lien
James E Tisdale
Katy E Trinkley
Kevin Yamanouye
Robert Lee Page
P304
P356
10.1185/03007995.2013.840568
P407
P577
2013-09-23T00:00:00Z